NASDAQ
6.28USD
-0.06 (-0.95%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
53.3M
P/E
—
EPS
—
Beta
1.74
52W range
2.61519-21.33873
Day range
6.28–6.52
Open
6.39
Prev close
6.34
Volume
14.4K
Avg volume
127.9K
Dividend
0.00
IPO
2021-03-05
https://www.newsfilecorp.com/release/310412/Datavault-AI-Inc.-DVLT-Securities-Fraud-Contact-Berger-Montague-To-Discuss-Your-Rights · 8/19/2026-0.20
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/wellgistics-health-appoints-brett-thompson-as-chief-technology-office-1191323 · 7/15/2026+0.10
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/wellgistics-health-executive-chairman-and-president-exercise-warrants-1184501 · 6/30/2026+0.00
https://www.globenewswire.com/news-release/2026/06/16/3312466/0/en/Scilex-Holding-Company-Announces-Dream-Bowl-I-Meme-Coin-Tokens-to-List-on-Biconomy-Exchange-as-Early-as-June-23-2026.html · 6/16/2026+0.40
https://www.globenewswire.com/news-release/2026/06/12/3310993/0/en/Scilex-Holding-Company-Scilex-Confirms-the-Previously-Announced-Payment-Date-of-June-15-2026-for-the-Dividend-of-Semnur-Pharmaceuticals-Inc-Common-Stock-to-Holders-of-Scilex-Common.html · 6/12/2026+0.20
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/wellgistics-health-refinances-outstanding-convertible-debt-and-raises-1171274 · 5/27/2026+0.20
https://www.globenewswire.com/news-release/2026/03/13/3255649/0/en/Scilex-Holding-Company-Files-Federal-Securities-Fraud-Lawsuit-Seeking-Recovery-of-Approximately-Ninety-Six-96-Million-Misappropriated-Collateral-Shares-of-Datavault-AI-Inc-from-Mar.html · 3/13/2026-0.60
https://www.marketbeat.com/originals/how-one-deal-validated-datavault-ais-massive-growth-strategy/ · 11/21/2025+0.30
https://www.globenewswire.com/news-release/2025/11/04/3180717/0/en/Datavault-AI-Inc-Announces-a-10M-Worldwide-Exclusive-License-Agreement-with-Scilex-Holding-Company-for-Tokenization-and-Monetization-of-Real-World-Assets-RWA-in-Genomic-DNA-Data-Di.html · 11/4/2025+0.80
https://www.globenewswire.com/news-release/2025/11/03/3179204/0/en/Datavault-AI-Announces-Record-Date-of-Nov-14-2025-for-Dream-Bowl-Draft-Meme-Coin-Distribution-to-All-Eligible-Scilex-and-Datavault-AI-Shareholders.html · 11/3/2025+0.50
https://www.accessnewswire.com/newsroom/en/industrial-and-manufacturing/datavaults-45-day-transformation-is-the-ai-story-nobody-saw-coming-nas-1089710 · 10/20/2025+0.20
https://www.globenewswire.com/news-release/2025/10/02/3160750/0/en/Datavault-AI-Converts-13-3-Million-in-Convertible-Debt-Strengthens-Balance-Sheet.html · 10/2/2025+0.20
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
